

October 21, 2022

Medlander Medical Technology Inc.
% Kevin Wang
Consultant
Chonconn Medical Device Consulting Co., Ltd.
Room 504, Block C, No. 1029 Nanhai Avenue, Nanshan District
Shenzhen, Guangdong 518067
China

Re: K222201

Trade/Device Name: Biological Feedback and Stimulation System

Regulation Number: 21 CFR 890.5850

Regulation Name: Powered Muscle Stimulator

Regulatory Class: Class II Product Code: IPF, KPI, HCC

Dated: July 7, 2022 Received: July 25, 2022

Dear Kevin Wang:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Tushar Bansal, PhD
Acting Assistant Director, Acute Injury Devices Team
DHT5B: Division of Neuromodulation
and Physical Medicine Devices
OHT5: Office of Neurological
and Physical Medicine Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120

Expiration Date: 06/30/2023 See PRA Statement below.

510(k) Number (if known)	
K222201	
Device Name	
Biological Feedback and Stimulation System	
Indications for Use (Describe)	

As a powered muscle stimulator the Biological Feedback and Stimulation System is indicated for thefollowing conditions:

- Relaxation of muscle spasm
- Prevention or retardation of disuse atrophy
- Increasing local blood circulation
- Muscle re-education
- Immediate post-surgical stimulation of calf muscles to prevent venous thrombosis
- Maintaining or increasing range of motion

As a biofeedback device the Biological Feedback and Stimulation Systemis indicated for thefollowing conditions:

• Biofeedback, relaxationand muscle re-education purposes

As a nonimplanted electrical continence device the Biological Feedback and Stimulation Systemisindicated for the following conditions:

- Acute and ongoing treatment of stress, urge or mixed urinary incontinence and where the following results may improve urinary control: Inhibition of the detrusor muscles through reflexive mechanisms and strengthening of pelvic floor muscles.
- Incontinence treatment for assessing EMG activity of the pelvic floor and accessory muscles such as the abdominal and the gluteus muscles.

Type of Use (Select one or both, as applicable) Select one or both, as applicable		
	Type of Lies (Salast and or both, as applicable)	
	Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(K) Summary

Prepared in accordance with the requirements of 21 CFR Part 807.92

Prepared Date: 2022/7/18Submission sponsor

Name: Medlander Medical Technology Inc.

Address: Building 5, Acceleration Zone, Nanjing Life Science and Technology, Innovation Park, No. 2 Qiande Road, Jiangning District, 211100 Nanjing, Jiangsu,

PEOPLE'S REPUBLIC OF CHINA.

Contact person: Wang Wang Title: Management Representative E-mail: wangwang@medlander.com

2. Submission correspondent

Name: Chonconn Medical Device Consulting Co., Ltd.

Address: Room 504, Block C, No. 1029 Nanhai Avenue, Nanshan District, Shenzhen,

Guangdong, P. R. China 518067 Contact person: Kevin Wang E-mail: kevin@chonconn.com

Tel: +86-755 33941160

3. Subject Device Information

Trade/Device Name	Biological Feedback and Stimulation System	
Model	MLD M2R, MLD M2A, MLD M2B, MLD M2D, MLD M4R,	
Model	MLD M4D, MLD M4E, MLD M4Plus	
	Powered muscle stimulator	
Common Name	Non-implantable electrical continence device	
	Biofeedback device	
Regulatory Class	Class II	
	21 CFR 890.5850	
Regulation number	21 CFR 876.5320	
	21 CFR 882.5050	
Product code:	IPF, KPI, HCC	
	Physical Medicine	
Review panel	Gastroenterology/Urology	
	Neurology	
Submission type	Traditional 510(K)	

4. Predicate Device

Shenzhen Konmed Technology Co., Ltd., Biofeedback Nerve and Muscle Stimulator under

5. Device Description

This Biological Feedback and Stimulation System is a new type of biofeedback and neuromuscular electrical stimulation therapy device through the evaluation of myoelectric signal acquisition, multimedia biofeedback training, electromyography triggered electrical stimulation, passive electrical stimulation training and treatment.

6. Intended use & Indication for use

As a powered muscle stimulator the Biological Feedback and Stimulation System is indicated for the following conditions:

- Relaxation of muscle spasm
- Prevention or retardation of disuse atrophy
- Increasing local blood circulation
- Muscle re-education
- Immediate post- surgical stimulation of calf muscles to prevent venous thrombosis
- Maintaining or increasing range of motion

As a biofeedback device the Biological Feedback and Stimulation System is indicated for the following conditions:

Biofeedback, relaxation and muscle re-education purposes

As a nonimplanted electrical continence device the Biological Feedback and Stimulation System is indicated for the following conditions:

- Acute and ongoing treatment of stress, urge or mixed urinary incontinence and where the following results may improve urinary control: Inhibition of the detrusor muscles through reflexive mechanisms and strengthening of pelvic floor muscles.
- Incontinence treatment for assessing EMG activity of the pelvic floor and accessory muscles such as the abdominal and the gluteus muscles.

7. Comparison to the Predicate Device

Features	Subject Device: Biological	Predicate Device: Biofeedback	Comparison
	Feedback and Stimulation System	Nerve and Muscle Stimulator	
	(K222201)	(K202648)	
Product	IPF, KPI, HCC	IPF, KPI, HCC	Same
Code			
Regulation	21 CFR 890.5850	21 CFR 890.5850	Same
Number	21 CFR 876.5320	21 CFR 876.5320	
	21 CFR 882.5050	21 CFR 882.5050	

Classification	Class II	Class II	Same
Type of use	Prescription	Prescription	Same
	As a powered muscle stimulator the	As a powered muscle stimulator the	Same
	Biological Feedback and	Biofeedback Nerve and Muscle	
	Stimulation System is indicated for	Stimulator is indicated for the	
	the following conditions:	following conditions:	
	Relaxation of muscle spasm	Relaxation of muscle spasm	
	Prevention or retardation of	Prevention or retardation of	
	disuse atrophy	disuse atrophy	
	Increasing local blood	 Increasing local blood 	
	circulation	circulation	
	Muscle re-education	Muscle re-education	
	Immediate post- surgical	Immediate post- surgical	
	stimulation of calf muscles to	stimulation of calf muscles to	
	prevent venous thrombosis	prevent venous thrombosis	
	Maintaining or increasing	Maintaining or increasing range	
	range of motion	of motion	
	As a biofeedback device the	As a biofeedback device the	
	Biological Feedback and	Biofeedback Nerve and Muscle	
	Stimulation System is indicated for	Stimulator is indicated for the	
T 11 0	the following conditions:	following conditions:	
Indications for	Biofeedback, relaxation and	Biofeedback, relaxation and	
Use	muscle re-education purposes	muscle re-education purposes	
	As a nonimplanted electrical	As a nonimplanted electrical	
	continence device the Biological	continence device the Biofeedback	
	Feedback and Stimulation System is	Nerve and Muscle Stimulator is	
	indicated for the following	indicated for the following	
	conditions:	conditions:	
	Acute and ongoing treatment	Acute and ongoing treatment of	
	of stress, urge or mixed	stress, urge or mixed urinary	
	urinary incontinence and	incontinence and where the	
	where the following results	following results may improve	
	may improve urinary control:	urinary control: Inhibition of the	
	Inhibition of the detrusor	detruser muscles through	
	muscles through reflexive	reflexive mechanisms and	
	mechanisms and	strengthening of pelvic floor	
	strengthening of pelvic floor	muscles.	
	muscles.	Incontinence treatment for	
	Incontinence treatment for	assessing EMG activity of the	
	assessing EMG activity of the	pelvic floor and accessory	
	pelvic floor and accessory	muscles such as the abdominal	

	muscles such as the	and the chutous muscles	
		and the gluteus muscles.	
	abdominal and the gluteus		
Patient	muscles.	Adult	C
Patient	Adult	Adult	Same
population			
Basic unit specific	I		
Power supply	14.8VDC, 5Ah	7.4V DC/1200mAh	Different
	rechargeable lithium battery	rechargeable lithium battery	
Method of Line	N/A	N/A	Same
Current			
Isolation			
Leakage current	N/A (Battery)	N/A (Battery)	Same
– Normal			
condition			
- Single fault			
condition			
Number of	4	2	Different
output modes			
Number of	4	2	Different
output channel			
Software/	Yes	Yes	Same
Firmware/			
Microprocessor			
control			
Automatic	Yes	Yes	Same
Overload trip			
Automatic no-	Yes	Yes	Same
load trip	100		
Patient override	Yes	Yes	Same
control method	103		Same
Indicator	Yes	Yes	Same
display	105	165	Same
-On/Off status			
-On/On status -Low battery			
-Low battery -Output mode			
-Time to cutoff			
-Voltage/current			
level	XV.		
Automatic Shut	Yes	Yes	Same
Off			
Timer range	1min∼60min, adjustable	1-99min, adjustable	Different

Dimensions	280mm × 280mm × 110mm	KM530:	Different
		140.5×25.5×69mm	
		KM531:	
		146.5×29×74mm	
Weight	2Kg	KM530: 192 g	Different
· · · · · · · · · · · · · · · · · · ·		KM531: 230g	
Housing	Plastic	Plastic	Same
material and			
construction			
Compliance	IEC 60601-1;	IEC 60601-1;	Similar
with voluntary	IEC 60601-1-2;	IEC 60601-1-2;	
standards	IEC 60601-2-10;	IEC 60601-2-10;	
	IEC 60601-2-40	IEC 60601-1-11;	
		IEC 60601-2-40	
Compliance	Yes	Yes	Same
with 21CFR			
898			
Output specifica	ations		
Waveform	Pulsed biphasic, The positive	Pulsed symmetric, asymmetric,	Different
	wave is rectangular and the	biphasic square wave	
	negative wave is spike		
Maximum	$50 \text{V} @ 500 \Omega$, error: $\pm 20\%$;	47.2V @ 500 Ω	Similar
output		108V @ 2k Ω	
voltage	145V@2K Ω , error: $\pm 20\%$;	150V@ 10k Ω	
	226V@10KΩ, error: \pm 20%		
Maximum	100 mA@500Ω, error: $\pm 20\%$;	94.4mA @ 500 Ω	Similar
output	72.5mA@2K Ω , error: $\pm 20\%$;	54mA @ 2k Ω	
current	22.6mA@10K Ω , error: $\pm 20\%$	15mA@ 10k Ω	
Net Charge	≤3.5 μ C @500Ω	For pulsed symmetric, biphasic:	Similar
(per pulse)	(3.3) ((3.50011	0 μ C @500 Ω;	
(per paise)		For pulsed asymmetric, biphasic:	
		15.68 μ C @ 500 Ω	
Maximum	≤11.5 μ C @500Ω	51.4 μ C @ 500 Ω	Similar
Phase			
Charge			
(500Ω)			
Maximum	$\leq 17.5 \text{ mA/cm}^2@500\Omega$	6.01mA/ cm2@ 500 Ω	Similar
current	9- ***		
density			
(500Ω)			
(500)			

Maximum	$\leq 0.01 \text{W/cm}^2 @500\Omega$	0.012W(12mW) / cm2@ 500 Ω	Similar
power			
density			
(500 Ω)			
Pulse	0.5Hz-1000Hz	2-100Hz	Similar
frequency			
Pulse	10 μ s~1000 μ s	50-450 μ s	Similar
duration			
Biofeedback perfe	ormance		
Number of	2	2	Same
EMG			
channel			
EMG	Bipolar	Bipolar	Same
detection			
(bipolar/			
monopolar)			
EMG range	1-3000 μ V	0.2-2000 µ V	Similar
(µ V)			
EMG	20Hz-550Hz	20Hz-500Hz	Similar
bandwidth			

8. Performance Data

The following performance data were provided in support of the substantial equivalence determination.

Biocompatibility testing

The biocompatibility evaluation for the proposed device was conducted in accordance with the FDA Guidance for Industry and Food and Drug Administration Staff: Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process". The battery of testing included the following tests:

- Cytotoxicity
- Skin Sensitization
- Vaginal and rectal irritation

Non-clinical data

Non-clinical testing has been conducted to verify that the Biological Feedback and Stimulation System meets all design specifications which supports the conclusion that it's Substantially Equivalent (SE) to the predicate device. The testing results demonstrate that the targeted device complies with the following standards:

• IEC 60601-1, Medical electrical equipment -- Part 1: General

- requirements for basic safety and essential performance
- IEC 60601-1-2, Medical electrical equipment Part 1-2: General requirements for basic safety and essential performance Collateral standard: Electromagnetic disturbances Requirements and tests
- IEC 60601-2-10, Medical electrical equipment -- Part 2-10: Particular requirements for the basic safety and essential performance of nerve and muscle stimulators
- IEC 60601-2-40, Medical electrical equipment Part 2-40: Particular requirements for the basic safety and essential performance of electromyographs and evoked response equipment

We have also conducted:

- Software verification and validation test according to the requirements of the FDA "Guidance for Pre-Market Submissions and for Software Contained in Medical Devices"
- The waveform test report has also been conducted to verify the output specifications of the device according to Guidance Document for Powered Muscle Stimulator 510(k)s

9. Conclusion

Performance testing and compliance with voluntary standards demonstrate that the proposed subject device is substantially equivalent to the predicate device.